Grace Therapeutics宣布私募融资3000万美元

2025-02-10 21:15

Grace Therapeutics (NASDAQ:GRCE), formerly Acasti Pharma, on Monday said it has signed securities purchase agreements with new and existing healthcare focused institutional investors to raise up to approximately $30 million in potential total gross proceeds.
The proceeds include initial upfront funding of about $15 million and the potential to receive up to an additional about $15 million upon cash exercise of accompanying warrants at the election of the investors.
Pursuant to the terms of the securities purchase agreements, Grace Therapeutics will issue an aggregate of 4.42 million shares of its common stock and accompanying common warrants to purchase up to an aggregate of 4.42 million shares of its common stock at a combined purchase price of $3.395 per share and accompanying warrants.
The company said the aggregate gross proceeds from the closing of the financing are expected to be approximately $15 million. The financing is expected to close on February 11, 2025.
Grace Therapeutics intends to use the upfront net proceeds from the private placement for general corporate purposes and to fund pre-commercial development of GTx-104, a clinical stage, novel, injectable formulation of nimodipine being developed for IV infusion in aSAH patients to address significant unmet medical needs.
GRCE -18.20% premarket to $2.65.
Source: Press Release

More on Grace Therapeutics